FDA Approved: TYKERB — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for TYKERB (lapatinib) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• Tykerb (lapatinib)

Snippet

SUPPL AP for TYKERB (LAPATINIB)